Biomaterials in Chimeric Antigen Receptor T-Cell Process Development.

Area of Science:

• Biomaterials Science
• Immunology
• Cellular Engineering

Background:

• Chimeric antigen receptor (CAR) T-cell therapy is a powerful cancer treatment, but its production is complex, lengthy, and expensive.
• Limitations in CAR T-cell manufacturing hinder broader clinical application and the treatment of diverse cancers.
• Innovation in cell manufacturing is crucial for the successful implementation of advanced CAR T-cell therapies.

Purpose of the Study:

• To leverage biomaterials to enhance the three fundamental steps of CAR T-cell manufacturing: isolation, activation, and genetic modification.
• To develop cost-effective and efficient methods for producing CAR T cells.
• To overcome current limitations in T-cell isolation, activation, and gene delivery.

Main Methods:

• Developed synthetic DNA aptamers and reversal agents for label-free isolation of CD8+ T cells.
• Engineered biodegradable, cell-templated silica microparticles with lipid bilayers for T-cell activation.
• Synthesized and evaluated cationic polymers for nonviral T-cell transfection.

Main Results:

• Aptamer-based isolation yielded high purity and comparable therapeutic potency of CAR T cells.
• Biomaterial-based T-cell activation promoted unbiased CD4/CD8 expansion without terminal differentiation.
• A comb-shaped cationic polymer demonstrated low cytotoxicity in T-cell transfection, though efficiency requires further improvement.

Conclusions:

• Biomaterial innovations can significantly improve the efficiency and reduce the cost of CAR T-cell manufacturing.
• These advancements address key bottlenecks in T-cell isolation, activation, and genetic modification.
• Future development of these technologies will enable more economical and straightforward CAR T-cell production.